BioMarin Acquires Amicus for $4.8 Billion, Broadening Rare Disease Portfolio
Event summary
- BioMarin completed its acquisition of Amicus Therapeutics for $4.8 billion in an all-cash deal, or $14.50 per share.
- The acquisition adds Galafold (Fabry disease) and Pombiliti + Opfolda (Pompe disease) to BioMarin's commercial portfolio.
- BioMarin also gains U.S. rights to DMX-200, a Phase 3 investigational treatment for FSGS.
- BioMarin expects to provide updated FY 2026 guidance during its Q1 earnings call on May 4, 2026.
The big picture
BioMarin’s $4.8 billion acquisition of Amicus Therapeutics represents a significant bet on the expanding rare disease therapeutics market. The deal provides BioMarin with immediate revenue streams from established therapies while also adding a promising late-stage asset in DMX-200, but also introduces integration challenges and regulatory dependencies that could impact future performance. This move underscores the ongoing consolidation within the rare disease sector, as companies seek to build scale and diversify their pipelines to address the unique challenges of developing and commercializing treatments for small patient populations.
What we're watching
- Integration Risk
- The success of the acquisition hinges on BioMarin’s ability to effectively integrate Amicus’ commercial operations and pipeline, a process that could be complicated by differing cultures and processes.
- Regulatory Scrutiny
- Continued approval of Galafold remains contingent on verification of clinical benefit in confirmatory trials, potentially exposing BioMarin to regulatory risk if those trials fail to meet expectations.
- Market Dynamics
- The competitive landscape for Pompe disease treatments is intensifying, and BioMarin will need to demonstrate Pombiliti + Opfolda’s value proposition to maintain market share and justify the acquisition price.
Related topics